13 July 2016
The agency says, for now, it’s business as usual.
The European Medicines Agency (EMA) says the future location of the agency will be determined by common agreement between representatives of the Member States, according to a July 6, 2016 statement. Until then, EMA says it will be conducting business as usual, and the outcome of the June 23 referendum will not affect the agency’s operations.
EMA wrote in the statement, “No Member State has ever decided to leave the EU, so there is no precedent for this situation. The implications for the seat and operations of EMA depend on the future relationship between the UK and the EU. This is unknown at present and therefore we will not engage in any speculations … We are confident that the Member States will take the most appropriate decision on EMA's location and arrangements in due course, taking also into account the complex political and legal environment generated by the outcome of the UK referendum.”
EMA is working closely with European Union institutions. The agency said it will update its stakeholders as soon as more information becomes available.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024